Annals On Call Podcast
American College of Physicians
Each Annals On Call podcast features Dr. Bob Centor discussing and debating a clinically influential article published in Annals of Internal Medicine with a guest expert.
Episodes
Mentioned books
Dec 1, 2025 • 25min
Cost-Effectiveness of Weight Loss Drugs for Knee Osteoarthritis
Dr. Centor discusses the use of weight loss drugs to treat patients with knee osteoarthritis with Dr. David Felson.
Nov 17, 2025 • 20min
Palliative Care: A Family Perspective
Dr. Centor discusses a family perspective on palliative care with Ms. Monica Wright, the author of an On Being a Patient essay.
Nov 3, 2025 • 16min
What You May Have Missed in 2024: Part 3
Dr. Centor revisits information included in the Annals of Internal Medicine supplement "What You May Have Missed in 2024."
Oct 20, 2025 • 14min
What You May Have Missed in 2024 - Part 2
Dr. Centor revisits information included in the Annals of Internal Medicine supplement "What You May Have Missed in 2024."
Oct 6, 2025 • 29min
High-Concentration Cannabinoids: Are They Safe?
Dr. Centor discusses currently available evidence about high-concentration cannabis products and mental health outcomes with Drs. Paula Riggs and Jonathan Samet.
Sep 15, 2025 • 20min
What You May Have Missed in 2024: Part 1
Dr. Centor revisits information included in the Annals of Internal Medicine supplement "What You May Have Missed in 2024."
Sep 1, 2025 • 23min
Fibrillation - When Ablation is the Way to Go
Dr. Centor discusses the role of ablation in the management of patients with atrial fibrillation with Dr. Peter Zimetbaum.
Aug 18, 2025 • 30min
Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes
Join Dr. Centor as he speaks with Kevin Kip, VP for Clinical Analytics at the University of Pittsburgh, and Anum Saeed, Assistant Professor of Cardiology at UPMC. They delve into the intriguing study comparing semaglutide and empagliflozin for type 2 diabetes, highlighting critical outcomes such as mortality and cardiovascular events. They break down complex topics like emulating clinical trials using electronic health records and discuss how demographic factors influence treatment adherence. Their insights pave the way for future diabetes treatment strategies.
Aug 4, 2025 • 21min
Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control is Inadequate on Dulaglutide
Dr. Centor discusses outcomes in patients with inadequately controlled type 2 diabetes when the dulaglutide dose is escalated versus switching to tirzepatide.
7 snips
Jul 14, 2025 • 24min
Diagnosing Primary Aldosteronism
Jordana Cohen, a nephrologist and clinical researcher at Penn, dives into the underutilization of screening for primary aldosteronism. She reveals that less than 2% of eligible individuals are tested and stresses the need for better diagnostic strategies. The conversation critiques current confirmatory testing methods and champions new approaches. Additionally, they discuss the rising use of mineralocorticoid blockers in hypertension treatment and compare options for resistant hypertension, highlighting effective alternatives like ameloride.
